
Bristol Myers Squibb bags European Commission nod for Subcutaneous formulation of Opdivo across multiple solid tumor ...
Princeton: Bristol Myers Squibb has received approval from the European Commission (EC) for a new Opdivo (nivolumab) formulation associated with a new route of administration (subcutaneous use [SC]), a new pharmaceutical form (solution for injection) and a …